GlassScriptPhysician profile
Omar Beckett
NPI 1013336874
$3,832.16
in general payments reported to CMS, 2019-2025
27 companies · $554 in 2025
The $554 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,789 · 2021: $14.94 · 2022: $197 · 2023: $752 · 2024: $526 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $1,788.55 | 2020 | |
| Eton Pharmaceuticals, INC. | $225.41 | 2023-2025 | Alkindi, Increlex, Khindivi |
| Novo Nordisk INC | $205.80 | 2022-2025 | Sogroya, Wegovy |
| Sanofi-Aventis U.S. LLC | $181.31 | 2023-2025 | |
| Abbvie INC. | $158.83 | 2022-2025 | Lupron Depot |
| Azurity Pharmaceuticals, INC. | $120.16 | 2023-2025 | Triptodur, Triptodur |
| Mannkind Corporation | $108.17 | 2023 | Afrezza |
| Ascendis Pharma Endocrinology INC | $99.98 | 2023-2025 | Skytrofa |
| Neurocrine Biosciences, INC. | $90.17 | 2025 | |
| Xeris Pharmaceuticals, INC. | $85.51 | 2024-2025 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $83.19 | 2022-2023 | Strensiq |
| Tandem Diabetes Care, INC. | $79.79 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $78.35 | 2022-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $72.89 | 2024 | Ilet Bionic Pancreas |
| Pfizer INC. | $56.73 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $48.61 | 2023 | Freestyle Libre 2 |
| Rhythm Pharmaceuticals, INC. | $47.84 | 2023-2025 | Imcivree, Imcivree |
| Kyowa Kirin, INC. | $47.29 | 2023-2024 | Crysvita |
| Lifescan, INC. | $43.01 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $42.88 | 2023-2024 | Baqsimi |
| Soleno Therapeutics, INC. | $40.69 | 2025 | Vykat Xr |
| Tolmar Pharmaceuticals, INC. | $33.93 | 2022 | |
| Sequel Med Tech, LLC | $20.65 | 2025 | Twiist |
| Lilly USA, LLC | $19.75 | 2022 | |
| Ibsa Pharma INC. | $19.00 | 2023 | Tirosint, Licart |
| Medtronic, INC. | $18.73 | 2024 | Mycarelink |
| Boston Scientific Corporation | $14.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Beckett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.